Tapimmune Inc (TPIV) 0.1900 $TPIV
Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"
PR Newswire - Mon Mar 30, 5:33PM CDT
TapImmune Inc. (OTCQB: TPIV), wishes to provide clarification on its participation at the Fifth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City on March 26. TapImmune was represented at this meeting by Dr. Glynn Wilson, Chairman & CEO of TapImmune and Dr. John Bonfiglio, Strategic Advisor to the Company. Regrettably, due to parallel meeting sessions running behind schedule, Dr. Wilson was unable to present a webcast at 4:30pm Eastern Time as originally scheduled in order to participate as an invited panellist in an important discussion on "What is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T Cell Immunotherapies?" Other panellists were Dr. Robert Stein, CSO of Agenus, Inc., Dr. Reiner Laus, CEO of Annias Immunotherapeutics, Dr. Robert Pierce, CMO of OncoSec Medical, and David Berd, CMO of AVAX Technologies. The panel discussion was moderated by Dr. Mac Cheever, MD, Fred Hutchinson Cancer Research Center, who also served as the Keynote speaker at the conference.
TapImmune to Present at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" on Thursday March 26, 2015
PR Newswire - Wed Mar 25, 8:58AM CDT
TapImmune Inc. (OTCBB: TPIV), a clinical stage immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today that Dr. Glynn Wilson, Chairman & CEO will present a corporate update at the Fifth Annual: "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City, at 4.30 Eastern Time ET. A live audio webcast of Dr. Wilson's presentation will be available on TapImmune's website at www.tapimmune.com and will be archived on the website for 30 days following the event.
TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors
PR Newswire - Thu Mar 19, 7:45AM CDT
TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company's Board of Directors.
TapImmune Receives $1,000,000 from Strategic Investor
PR Newswire - Tue Mar 10, 7:30AM CDT
TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a US$1 million investment from Eastern Capital Limited under the same terms as the recent January 12, 2015 round of financing.
TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations
PR Newswire - Thu Feb 19, 8:30AM CST
TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today the Company's management team has selected New York City based PCG Advisory (PCG) as agency of record for Investor, Public, and Social Media Relations. After a competitive process, TapImmune determined PCG presented a team that was best matched for the Company's strategic growth plans. In addition, the PCG team presented strong knowledge of the Company's science and financial goals.
TapImmune's CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" for Phase II Trials
Marketwired - Tue Feb 10, 6:02AM CST
TapImmune Inc. (OTCQB: TPIV), the emerging clinical-stage immunotherapy company which develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases has been grabbing the attention of biotech investors as they ready multiple products for Phase II Clinical Trials. Armed with impressive data results and money from a recent financing, Dr. Glynn Wilson, TapImmune's CEO sat down with BioMedReports to discuss the firm's pipeline progress and challenges.
Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials
PR Newswire - Mon Jan 12, 8:19AM CST
TapImmune Inc. (OTCQB: TPIV) is extremely pleased to report the completion of data analysis from all 21 evaluable patients treated in a Phase I clinical trial. In addition, the recent financing provides immediate, short term and long term access to the capital required to execute its exclusive option to license these very promising peptides and to progress its on-going clinical program into Phase II trials.
TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering
PR Newswire - Mon Jan 12, 7:48AM CST
TapImmune, Inc. (the "Company"
, (otcqb:TPIV), today announced that it has entered into a definitive agreement with institutional investors for a registered direct placement of 7,320,000 units at $0.20 per unit, with each "unit" consisting of one share of common stock and one of each of the following warrants:
TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews
PR Newswire - Mon Nov 24, 8:06AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has been interviewed. In light of the company's recent news about the establishment of a Phase 2 collaboration and advancement of both clinical programs, the company would like to direct its shareholders to these articles and interviews where Dr Wilson has discussed the progression of clinical trials and TapImmune's technology approach.
Published Review and Analyst Report Boost TapImmune Shares
Marketwired - Wed Nov 19, 3:21PM CST
TapImmune, Inc. (OTCQB: TPIV) was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, Ph.D.
VGTI Florida to Collaborate with TapImmune to Advance Targeted Breast and Ovarian Cancer Vaccines into Phase II Clinical Trials
Business Wire - Tue Nov 18, 10:40AM CST
The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, today announced a new collaborative research agreement with TapImmune, Inc. (OTCQB: TPIV), forming a partnership to advance TapImmune's proprietary, targeted cancer vaccines into mid-stage, Phase II human clinical trials for the treatment of breast and ovarian cancers.
TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines
PR Newswire - Tue Nov 18, 9:00AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.
Could This Emerging Drug Developer Really Be Worth A Billion Dollars In Five Years?
ACCESSWIRE - Mon Nov 17, 7:02AM CST
Los Angeles, CA / ACCESSWIRE / November 17, 2014 / Chief Executive Officers of publicly traded companies are often warned not speculate about the future valuation of their firms and that's precisely part of the reason investors are looking more closely at the recent "on the record" statements made by TapImmune's (OTCBB:TPIV) Dr. Glynn Wilson to the Life Sciences Intellectual Property Review.
KITE: 58.34 (+0.22)
The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies
ACCESSWIRE - Wed Nov 05, 8:24AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it was recently interviewed by The Life Sciences Report regarding the microcap market for life sciences companies, during which SeeThruEquity analysts discussed DelMar Pharmaceuticals Inc. (OTCQB: DMPI), Manhattan Scientifics Inc. (OTCQB: MHTX) and TapImmune Inc. (OTCQB: TPIV).
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.78 (-0.18), NWBO: 8.30 (-0.14), GALE: 1.38 (-0.02), LBIO: 12.39 (unch)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 9.78 (-0.18), MRK: 57.25 (-0.18), PFE: 35.44 (+0.41), SRPT: 13.85 (-0.21), NLNK: 55.38 (-0.33), TKMR: 18.19 (+0.59), GSK: 48.23 (+0.51), NVS: 103.58 (+1.01)
TapImmune Provides Update on PolyStart(TM) Vaccine Platform Applicable to Cancer and Infectious Disease
Business Wire - Wed Oct 22, 7:30AM CDT
TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStart(TM) vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. While the current focus of the Company's PolyStart technology is on TapImmune's cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this core technology has widespread applicability in the development of vaccines for viral disease.
What's Next: Investors Place Ebola Pandemic Stock Bets
ACCESSWIRE - Mon Oct 06, 6:59AM CDT
Los Angeles, CA / October 6, 2014 / The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA's awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.
INO: 9.78 (-0.18), HEB: 0.23 (+0.01), TKMR: 18.19 (+0.59)
SeeThruEquity Issues Company Update on TapImmune Highlighting Positive Clinical Trial Data
ACCESSWIRE - Thu Sep 18, 8:03AM CDT
SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor alpha antigens in ovarian and breast cancer
TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
Business Wire - Tue Sep 16, 7:30AM CDT
TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes. All five of the constituent peptides were found to be immunogenic and all patients developed immune responses to at least one and in most cases more than one of the vaccine peptides.
Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"
PR Newswire - Mon Mar 30, 5:33PM CDT
TapImmune Inc. (OTCQB: TPIV), wishes to provide clarification on its participation at the Fifth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City on March 26. TapImmune was represented at this meeting by Dr. Glynn Wilson, Chairman & CEO of TapImmune and Dr. John Bonfiglio, Strategic Advisor to the Company. Regrettably, due to parallel meeting sessions running behind schedule, Dr. Wilson was unable to present a webcast at 4:30pm Eastern Time as originally scheduled in order to participate as an invited panellist in an important discussion on "What is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T Cell Immunotherapies?" Other panellists were Dr. Robert Stein, CSO of Agenus, Inc., Dr. Reiner Laus, CEO of Annias Immunotherapeutics, Dr. Robert Pierce, CMO of OncoSec Medical, and David Berd, CMO of AVAX Technologies. The panel discussion was moderated by Dr. Mac Cheever, MD, Fred Hutchinson Cancer Research Center, who also served as the Keynote speaker at the conference.
TapImmune to Present at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" on Thursday March 26, 2015
PR Newswire - Wed Mar 25, 8:58AM CDT
TapImmune Inc. (OTCBB: TPIV), a clinical stage immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today that Dr. Glynn Wilson, Chairman & CEO will present a corporate update at the Fifth Annual: "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City, at 4.30 Eastern Time ET. A live audio webcast of Dr. Wilson's presentation will be available on TapImmune's website at www.tapimmune.com and will be archived on the website for 30 days following the event.
TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors
PR Newswire - Thu Mar 19, 7:45AM CDT
TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company's Board of Directors.
TapImmune Receives $1,000,000 from Strategic Investor
PR Newswire - Tue Mar 10, 7:30AM CDT
TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a US$1 million investment from Eastern Capital Limited under the same terms as the recent January 12, 2015 round of financing.
TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations
PR Newswire - Thu Feb 19, 8:30AM CST
TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today the Company's management team has selected New York City based PCG Advisory (PCG) as agency of record for Investor, Public, and Social Media Relations. After a competitive process, TapImmune determined PCG presented a team that was best matched for the Company's strategic growth plans. In addition, the PCG team presented strong knowledge of the Company's science and financial goals.
TapImmune's CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" for Phase II Trials
Marketwired - Tue Feb 10, 6:02AM CST
TapImmune Inc. (OTCQB: TPIV), the emerging clinical-stage immunotherapy company which develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases has been grabbing the attention of biotech investors as they ready multiple products for Phase II Clinical Trials. Armed with impressive data results and money from a recent financing, Dr. Glynn Wilson, TapImmune's CEO sat down with BioMedReports to discuss the firm's pipeline progress and challenges.
Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials
PR Newswire - Mon Jan 12, 8:19AM CST
TapImmune Inc. (OTCQB: TPIV) is extremely pleased to report the completion of data analysis from all 21 evaluable patients treated in a Phase I clinical trial. In addition, the recent financing provides immediate, short term and long term access to the capital required to execute its exclusive option to license these very promising peptides and to progress its on-going clinical program into Phase II trials.
TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering
PR Newswire - Mon Jan 12, 7:48AM CST
TapImmune, Inc. (the "Company"
, (otcqb:TPIV), today announced that it has entered into a definitive agreement with institutional investors for a registered direct placement of 7,320,000 units at $0.20 per unit, with each "unit" consisting of one share of common stock and one of each of the following warrants: TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews
PR Newswire - Mon Nov 24, 8:06AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has been interviewed. In light of the company's recent news about the establishment of a Phase 2 collaboration and advancement of both clinical programs, the company would like to direct its shareholders to these articles and interviews where Dr Wilson has discussed the progression of clinical trials and TapImmune's technology approach.
Published Review and Analyst Report Boost TapImmune Shares
Marketwired - Wed Nov 19, 3:21PM CST
TapImmune, Inc. (OTCQB: TPIV) was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, Ph.D.
VGTI Florida to Collaborate with TapImmune to Advance Targeted Breast and Ovarian Cancer Vaccines into Phase II Clinical Trials
Business Wire - Tue Nov 18, 10:40AM CST
The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, today announced a new collaborative research agreement with TapImmune, Inc. (OTCQB: TPIV), forming a partnership to advance TapImmune's proprietary, targeted cancer vaccines into mid-stage, Phase II human clinical trials for the treatment of breast and ovarian cancers.
TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines
PR Newswire - Tue Nov 18, 9:00AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.
Could This Emerging Drug Developer Really Be Worth A Billion Dollars In Five Years?
ACCESSWIRE - Mon Nov 17, 7:02AM CST
Los Angeles, CA / ACCESSWIRE / November 17, 2014 / Chief Executive Officers of publicly traded companies are often warned not speculate about the future valuation of their firms and that's precisely part of the reason investors are looking more closely at the recent "on the record" statements made by TapImmune's (OTCBB:TPIV) Dr. Glynn Wilson to the Life Sciences Intellectual Property Review.
KITE: 58.34 (+0.22)
The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies
ACCESSWIRE - Wed Nov 05, 8:24AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it was recently interviewed by The Life Sciences Report regarding the microcap market for life sciences companies, during which SeeThruEquity analysts discussed DelMar Pharmaceuticals Inc. (OTCQB: DMPI), Manhattan Scientifics Inc. (OTCQB: MHTX) and TapImmune Inc. (OTCQB: TPIV).
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.78 (-0.18), NWBO: 8.30 (-0.14), GALE: 1.38 (-0.02), LBIO: 12.39 (unch)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 9.78 (-0.18), MRK: 57.25 (-0.18), PFE: 35.44 (+0.41), SRPT: 13.85 (-0.21), NLNK: 55.38 (-0.33), TKMR: 18.19 (+0.59), GSK: 48.23 (+0.51), NVS: 103.58 (+1.01)
TapImmune Provides Update on PolyStart(TM) Vaccine Platform Applicable to Cancer and Infectious Disease
Business Wire - Wed Oct 22, 7:30AM CDT
TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStart(TM) vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. While the current focus of the Company's PolyStart technology is on TapImmune's cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this core technology has widespread applicability in the development of vaccines for viral disease.
What's Next: Investors Place Ebola Pandemic Stock Bets
ACCESSWIRE - Mon Oct 06, 6:59AM CDT
Los Angeles, CA / October 6, 2014 / The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA's awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.
INO: 9.78 (-0.18), HEB: 0.23 (+0.01), TKMR: 18.19 (+0.59)
SeeThruEquity Issues Company Update on TapImmune Highlighting Positive Clinical Trial Data
ACCESSWIRE - Thu Sep 18, 8:03AM CDT
SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor alpha antigens in ovarian and breast cancer
TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
Business Wire - Tue Sep 16, 7:30AM CDT
TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes. All five of the constituent peptides were found to be immunogenic and all patients developed immune responses to at least one and in most cases more than one of the vaccine peptides.
